Molecular Markers in Treatment in Endometrial Cancer

Prospective Study of Endometrial Cancer Treatment in Relation to Molecular Markers in Curettage Specimens.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00598845

Acronym

MoMaTEC

Enrollment

1000

Registered

2008-01-23

Start date

2001-04-30

Completion date

2017-12-31

Last updated

2014-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial Neoplasms, Neoplasm Metastasis

Keywords

Endometrial cancer, Molecular markers, Lymph node metastasis, Prospective study, Prognosis, Cancer of Endometrium, Tumor Markers, Biological

Brief summary

The purpose of this prospective multicenter trial is to investigate the value of molecular markers in endometrial cancer for predicting lymph node metastasis and prognosis in relation to treatment.

Detailed description

This is a prospective multicenter study to investigate the predictive value of molecular markers in endometrial cancer for lymph node metastasis, prognosis and treatment. For the previously studied tumor markers p53, p16, ER, PR and HER2neu, we want to investigate the expression in curettage material in relation to lymph node metastasis and prognosis among endometrial carcinoma patients. We also want to investigate the distribution of genetic alterations in fresh frozen tumor tissue in order to design prospective randomized treatment trials of metastatic endometrial cancer based on molecular profile. There will be a special emphasis on disturbances in the pathways influenced by new targeted therapy, such as inhibitors of Her2/NEU, EGFR, receptor tyrosine kinase, mTOR, PTEN and hormone receptor pathways.

Interventions

PROCEDURETumor biopsy study

Tumor specimens from endometrial cancer patients, collected preoperatively and during primary hysterectomy, are investigated.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

* Women with endometrial carcinoma * Available endometrial biopsy * Informed consent

Exclusion criteria

* No informed consent

Design outcomes

Primary

Measure	Time frame
Presence of lymph node metastases	At primary treatment

Secondary

Measure	Time frame
Recurrent disease, death from disease	5 years after primary treatment

Countries

Belgium, Norway, Sweden

Contacts

Primary ContactBritt Edvardsen, AVD ING

britt.edvardsen@helse-bergen.no+4755974200

Backup ContactIngjerd Bergo, Tech

ingjerd.bergo@helse-bergen.no+4755974200

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026